ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
Please provide your email address to receive an email when new articles are posted on . Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs.
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. If you have the appropriate ...
Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
AstraZeneca has already provided the requested information to the FDA and a decision on the updated BLA is expected in the first half of 2026.
Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma Authors retain all rights in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results